Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAPEDS 1 pediatric tralokinumab PK and safety in atopic dermatitis
2024-512791-36-00Phase 2Completed
- Sponsor
- LEO Pharma
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, randomised, single-blind trial of tralokinumab in atopic dermatitis (AD) (2 arms), sponsored by LEO Pharma. Primary endpoints: Ctrough at Week 16, Cmax between Week 12-Week 14 for Q2W; Week 12-Week 16 for Q4W and 2 more. Started Aug 2022; status: completed.
02
Drugs
tralokinumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2024-512791-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512791-36-00.